The efficacy and safety of intravenous immunoglobulin infusion in 12 h for the initial treatment of Kawasaki disease

Background: Approximately 10–20 % of individuals develop a recrudescent or persistent fever after intravenous immunoglobulin (IVIG) infusion for the initial treatment of Kawasaki disease. The aim of this study was to evaluate the efficacy and safety of the initial IVIG treatment of Kawasaki disease...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Satoshi Asano, Naoya Fukushima, Kenichiro Yamada
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-09-01
Edice:	Pediatrics and Neonatology
Témata:	Coronary artery abnormalities Infusion duration Intravenous immunoglobulin IVIG safety Kawasaki disease
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S1875957224000032
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!